Actuate Therapeutics has announced the terms for its IPO, which is expected to raise USD 50 million.
Under the IPO, the company will offer 5.6 million shares at USD 8–10 per share. The expected use of the proceeds was undisclosed.
Actuate Therapeutics is a clinical-stage biotechnology company focused on developing oncology therapeutics through the inhibition of glycogen synthase kinase-3 (GSK-3). Its pipeline includes Actuate-1801, an Elragusib injection currently in clinical trials for treating refractory cancer and pancreatic cancer in adults. Other pipeline candidates include Actuate 1902, Elragusib injection for pediatric patients, and oral tablets for adult and pediatric patients with refractory cancer.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.